Apellis Pharmaceuticals Inc (APLS.OQ)
APLS.OQ on NASDAQ Stock Exchange Global Select Market
13.86USD
18 Oct 2018
13.86USD
18 Oct 2018
Change (% chg)
$-0.00 (-0.00%)
$-0.00 (-0.00%)
Prev Close
$13.86
$13.86
Open
$16.10
$16.10
Day's High
$16.10
$16.10
Day's Low
$13.07
$13.07
Volume
367,365
367,365
Avg. Vol
152,007
152,007
52-wk High
$31.69
$31.69
52-wk Low
$12.51
$12.51
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2018 | Jun '18 | 0.00 | -0.609 |
| Mar '18 | 0.00 | -0.432 | |
| FY 2017 | Dec '17 | 0.00 | -0.371 |
| Sep '17 | 0.00 | -0.235 | |
| Jun '17 | 0.00 | -0.246 | |
| Mar '17 | 0.00 | -0.184 | |
| FY 2016 | Dec '16 | 0.00 | -0.134 |
| Sep '16 | 0.00 | -0.146 | |
| Jun '16 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Dec-18 | 2 | 0.00 | 0.00 | 0.00 | -- |
| Quarter Ending Mar-19 | 1 | 0.00 | 0.00 | 0.00 | -- |
| Year Ending Dec-18 | 4 | 0.00 | 0.00 | 0.00 | -- |
| Year Ending Dec-19 | 4 | 0.00 | 0.00 | 0.00 | -- |
| Earnings (per share) | |||||
| Quarter Ending Dec-18 | 4 | -0.74 | -0.64 | -0.90 | -- |
| Quarter Ending Mar-19 | 3 | -0.73 | -0.70 | -0.77 | -- |
| Year Ending Dec-18 | 5 | -2.34 | -1.85 | -2.75 | -- |
| Year Ending Dec-19 | 5 | -2.71 | -1.97 | -3.24 | -- |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | -- | 30.92 | 33.69 | |
| P/E High - Last 5 Yrs. | -- | 40.54 | 45.21 | |
| P/E Low - Last 5 Yrs. | -- | 23.30 | 23.79 | |
| Beta | -- | 0.89 | 0.88 | |
| Price to Sales (TTM) | -- | 3.94 | 5.82 | |
| Price to Book (MRQ) | -- | 4.77 | 4.89 | |
| Price to Tangible Book (MRQ) | -- | 5.61 | 6.52 | |
| Price to Cash Flow (TTM) | -- | 22.57 | 22.95 | |
| % Owned Institutions | -- | 1.13 | 2.14 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 1.58 | 1.51 | |
| Dividend Yield - 5 Year Avg | -- | 1.58 | 1.52 | |
| Dividend 5 Year Growth Rate | -- | 4.41 | 5.39 | |
| Payout Ratio(TTM) | -- | 46.20 | 43.91 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | -- | 2.20 | 8.02 | |
| Sales (TTM) vs TTM 1 Yr. Ago | -- | 4.64 | 5.75 | |
| Sales - 5 Yr. Growth Rate | -- | 9.69 | 9.88 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | -- | 19.84 | 23.65 | |
| EPS (TTM) vs TTM 1 Yr. Ago | -- | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 9.96 | 10.95 | |
| Capital Spending - 5 Yr. Growth Rate | -- | 15.10 | 14.90 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | -- | 2.18 | 2.25 |
| Current Ratio (MRQ) | -- | 2.97 | 3.05 |
| LT Debt to Equity (MRQ) | -- | 9.93 | 12.73 |
| Total Debt to Equity (MRQ) | -- | 13.96 | 17.15 |
| Interest Coverage (TTM) | -- | 41.56 | 37.58 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | -- | 55.19 | 54.90 | |
| Gross Margin - 5 Yr. Avg. | -- | 52.30 | 52.43 | |
| EBITD Margin (TTM) | -- | -- | -- | |
| EBITD - 5 Yr. Avg | -- | 18.47 | 11.08 | |
| Operating Margin (TTM) | -- | 14.32 | 4.31 | |
| Operating Margin - 5 Yr. Avg. | -- | 14.35 | 6.43 | |
| Pre-Tax Margin (TTM) | -- | 14.86 | 5.36 | |
| Pre-Tax Margin - 5 Yr. Avg. | -- | 14.80 | 6.86 | |
| Net Profit Margin (TTM) | -- | 11.08 | 1.64 | |
| Net Profit Margin - 5 Yr. Avg. | -- | 11.07 | 3.11 | |
| Effective Tax Rate (TTM) | -- | 23.36 | 23.24 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 23.60 | 24.16 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | -- | 911,321,905 | 810,573,943 | |
| Net Income/Employee (TTM) | -- | 107,240,547 | 95,338,757 | |
| Receivable Turnover (TTM) | -- | 5.62 | 5.77 | |
| Inventory Turnover (TTM) | -- | 2.61 | 3.62 | |
| Asset Turnover (TTM) | -- | 0.95 | 0.92 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | -- | 11.37 | 10.92 | |
| Return on Assets - 5 Yr. Avg. | -- | 12.61 | 12.03 | |
| Return on Investment (TTM) | -- | 14.76 | 14.30 | |
| Return on Investment - 5 Yr. Avg. | -- | 16.44 | 15.63 | |
| Return on Equity (TTM) | -- | 16.26 | 16.03 | |
| Return on Equity - 5 Yr. Avg. | -- | 17.51 | 16.90 | |
Note: Units in Millions of US Dollars
Performance for Apellis Pharmaceuticals Inc
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | -- | -- | -- | 23 |
| 13 Week | -- | -- | -- | 33 |
| 26 Week | -- | -- | -- | 28 |
| 52 Week | -- | -- | -- | 12 |
| YTD | -- | -- | -- | 25 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
Institutional Holders
| % Shares Owned: | 58.81% |
| # of Holders: | 117 |
| Total Shares Held: | 33,037,040 |
| 3 Mo. Net Change: | 144,855 |
| # New Positions: | 2 |
| # Closed Positions: | 0 |
| # Increased Positions: | 15 |
| # Reduced Positions: | 1 |
| # Net Buyers: | 14 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.